Luciano Rossetti, MD

Luciano Rossetti, MD, head of Global Scientific Strategy, Merck Research Laboratories, talks about the discovery of PD-L1 and how the finding has evolved into potential treatments for bladder cancer patients, specifically avelumab.

Avelumab targets PD-L1 and blocks its interaction with PD-1 and ultimately deters the tumor in paralyzing a patient&rsquo;s immune response. Rossetti says that anti-PD-L1 therapies are being looked at as monotherapies, first- and second-line therapies, as well as being used in combination with other therapies.

Luciano Rossetti, MD | Authors

Articles

Dr. Luciano Rossetti on the Function of Anti-PD-L1 Treatments in Bladder Cancer